Gain from adding Roche's Avastin to immune drug unclear

September 28, 2014 2:56 PM

13 0

MADRID, Sept 28 (Reuters) - It is too early to say whether combining Roche's best-selling Avastin cancer drug with the company's experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumours.

That is the verdict of experts following a presentation of a small clinical study assessing the combination in patients with a variety of solid tumours.

Read more

To category page